Stryker Corporation (SYK) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
↑
20.38
↓-13% vs avg
5yr avg: 23.55
30Y Low8.2·High30.0
P/FCF
↓
26.40
↓-31% vs avg
5yr avg: 38.21
30Y Low14.5·High64.3
P/B Ratio
↓
5.03
↓-20% vs avg
5yr avg: 6.28
30Y Low2.4·High11.9
ROE
↑
15.1%
-3% vs avg
5yr avg: 15.5%
30Y Low3%·High33%
Debt/EBITDA
↓
2.44
↓-5% vs avg
5yr avg: 2.57
30Y Low0.0·High29.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SYK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Stryker Corporation trades at 35.1x earnings, 18% below its 5-year average of 43.1x, sitting at the 48th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 58%. On a free-cash-flow basis, the stock trades at 26.4x P/FCF, 31% below the 5-year average of 38.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $113.1B | $134.3B | $138.8B | $114.9B | $93.4B | $102.2B | $93.2B | $79.8B | $59.6B | $58.9B | $45.3B |
| Enterprise Value | $123.9B | $145.2B | $149.3B | $125.4B | $105.1B | $112.2B | $104.7B | $86.9B | $65.9B | $63.5B | $48.9B |
| P/E Ratio → | 35.15 | 41.84 | 46.40 | 36.30 | 39.63 | 51.23 | 58.34 | 38.31 | 16.78 | 57.78 | 27.54 |
| P/S Ratio | 4.50 | 5.35 | 6.14 | 5.61 | 5.06 | 5.98 | 6.49 | 5.36 | 4.38 | 4.73 | 4.00 |
| P/B Ratio | 5.03 | 5.99 | 6.73 | 6.18 | 5.62 | 6.87 | 7.12 | 6.23 | 5.08 | 5.90 | 4.75 |
| P/FCF | 26.40 | 31.36 | 39.82 | 36.64 | 45.90 | 37.34 | 33.40 | 51.72 | 29.25 | 61.24 | 31.82 |
| P/OCF | 22.42 | 26.63 | 32.73 | 30.96 | 35.61 | 31.33 | 28.44 | 36.40 | 22.84 | 37.75 | 23.68 |
P/E links to full P/E history page with 30-year chart
SYK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Stryker Corporation's enterprise value stands at 20.4x EBITDA, 13% below its 5-year average of 23.5x. The Healthcare sector median is 14.0x, placing the stock at a 45% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.78 | 6.61 | 6.12 | 5.70 | 6.56 | 7.29 | 5.84 | 4.84 | 5.11 | 4.32 |
| EV / EBITDA | 20.38 | 23.87 | 24.43 | 23.63 | 22.22 | 23.60 | 27.26 | 20.86 | 17.21 | 18.64 | 15.67 |
| EV / EBIT | 25.35 | 28.35 | 38.40 | 31.13 | 34.81 | 42.85 | 46.13 | 30.50 | 25.14 | 27.50 | 22.78 |
| EV / FCF | — | 33.90 | 42.82 | 40.00 | 51.63 | 40.98 | 37.52 | 56.35 | 32.31 | 66.11 | 34.35 |
SYK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Stryker Corporation earns an operating margin of 19.5%. Operating margins have compressed from 20.9% to 19.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 15.1% indicates solid capital efficiency. ROIC of 11.4% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.0% | 64.0% | 61.9% | 61.0% | 59.8% | 62.6% | 61.0% | 63.0% | 63.2% | 63.5% | 64.0% |
| Operating Margin | 19.5% | 19.5% | 22.4% | 20.9% | 20.2% | 22.0% | 21.1% | 22.8% | 22.8% | 22.2% | 22.8% |
| Net Profit Margin | 12.9% | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.1% | 15.1% | 15.3% | 18.0% | 15.0% | 14.3% | 12.4% | 17.0% | 32.7% | 10.4% | 18.2% |
| ROA | 7.1% | 7.1% | 7.2% | 8.2% | 6.6% | 5.8% | 5.0% | 7.3% | 14.4% | 4.8% | 9.0% |
| ROIC | 11.4% | 11.4% | 12.6% | 11.2% | 10.5% | 11.4% | 10.2% | 13.4% | 14.3% | 14.9% | 17.4% |
| ROCE | 13.0% | 13.0% | 15.0% | 13.7% | 12.3% | 12.7% | 11.0% | 14.1% | 15.0% | 15.0% | 16.5% |
SYK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Stryker Corporation carries a Debt/EBITDA ratio of 2.4x, which is manageable (22% below the sector average of 3.1x). Net debt stands at $10.8B ($14.9B total debt minus $4.0B cash). Interest coverage of 8.4x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.66 | 0.68 | 0.73 | 0.81 | 0.87 | 1.10 | 0.90 | 0.84 | 0.72 | 0.72 |
| Debt / EBITDA | 2.44 | 2.44 | 2.31 | 2.54 | 2.86 | 2.71 | 3.76 | 2.75 | 2.58 | 2.12 | 2.21 |
| Net Debt / Equity | — | 0.48 | 0.51 | 0.57 | 0.70 | 0.67 | 0.88 | 0.56 | 0.53 | 0.47 | 0.38 |
| Net Debt / EBITDA | 1.78 | 1.78 | 1.71 | 1.98 | 2.47 | 2.09 | 2.99 | 1.71 | 1.63 | 1.37 | 1.15 |
| Debt / FCF | — | 2.53 | 3.00 | 3.36 | 5.74 | 3.64 | 4.12 | 4.63 | 3.06 | 4.87 | 2.52 |
| Interest Coverage | 8.44 | 8.44 | 9.82 | 11.32 | 8.96 | 7.77 | 7.20 | 9.93 | 9.92 | 9.35 | 9.43 |
SYK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.89x means Stryker Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.21x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.58x to 1.89x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | 1.89 | 1.95 | 1.58 | 1.63 | 2.20 | 1.93 | 2.58 | 2.02 | 2.43 | 3.08 |
| Quick Ratio | 1.21 | 1.21 | 1.32 | 0.97 | 1.00 | 1.47 | 1.23 | 1.84 | 1.41 | 1.68 | 2.28 |
| Cash Ratio | 0.53 | 0.53 | 0.59 | 0.39 | 0.31 | 0.66 | 0.60 | 1.01 | 0.77 | 0.85 | 1.32 |
| Asset Turnover | — | 0.52 | 0.53 | 0.51 | 0.50 | 0.49 | 0.42 | 0.49 | 0.50 | 0.56 | 0.55 |
| Inventory Turnover | 1.70 | 1.70 | 1.80 | 1.65 | 1.85 | 1.93 | 1.60 | 1.68 | 1.69 | 1.84 | 2.01 |
| Days Sales Outstanding | — | 58.70 | 64.41 | 67.04 | 70.53 | 64.47 | 68.70 | 70.94 | 62.58 | 64.47 | 63.40 |
SYK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Stryker Corporation returns 1.1% to shareholders annually primarily through dividends. The payout ratio of 39.6% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 2.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.1% | 1.0% | 0.9% | 1.0% | 1.1% | 0.9% | 0.9% | 1.0% | 1.2% | 1.1% | 1.3% |
| Payout Ratio | 39.6% | 39.6% | 40.7% | 36.0% | 44.6% | 47.6% | 54.0% | 37.4% | 19.8% | 62.4% | 34.5% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.8% | 2.4% | 2.2% | 2.8% | 2.5% | 2.0% | 1.7% | 2.6% | 6.0% | 1.7% | 3.6% |
| FCF Yield | 3.8% | 3.2% | 2.5% | 2.7% | 2.2% | 2.7% | 3.0% | 1.9% | 3.4% | 1.6% | 3.1% |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.4% | 0.5% | 0.4% | 0.0% |
| Total Shareholder Yield | 1.1% | 1.0% | 1.0% | 1.1% | 1.3% | 1.0% | 1.0% | 1.4% | 1.7% | 1.5% | 1.3% |
| Shares Outstanding | — | $382M | $386M | $384M | $382M | $382M | $380M | $380M | $380M | $380M | $379M |
Peer Comparison
Compare SYK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SYKYou | $113B | 35.1 | 20.4 | 26.4 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $16B | 23.4 | 9.4 | 11.0 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
 BSX | $83B | 28.9 | 25.1 | 22.7 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 EW | $48B | 45.3 | 25.4 | 35.8 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 BDX | $52B | 24.7 | 14.0 | 19.6 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 MDT | $100B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SNN | $13B | 21.7 | 10.2 | 15.6 | 68.0% | 16.3% | 11.9% | 9.4% | 2.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 GMED | $12B | 23.0 | 19.6 | 20.7 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 ATRC | $1B | -122.7 | 82.6 | 30.9 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 INVA | $2B | 6.9 | 5.6 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full SYK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SYK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYK vs ZBH
Side-by-side business, growth, and profitability comparison vs Zimmer Biomet Holdings, Inc..
Start ComparisonSYK — Frequently Asked Questions
Quick answers to the most common questions about buying SYK stock.
What is Stryker Corporation's P/E ratio?
Stryker Corporation's current P/E ratio is 35.1x. The historical average is 36.9x. This places it at the 48th percentile of its historical range.
What is Stryker Corporation's EV/EBITDA?
Stryker Corporation's current EV/EBITDA is 20.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.7x.
What is Stryker Corporation's ROE?
Stryker Corporation's return on equity (ROE) is 15.1%. The historical average is 17.8%.
Is SYK stock overvalued?
Based on historical data, Stryker Corporation is trading at a P/E of 35.1x. This is at the 48th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Stryker Corporation's dividend yield?
Stryker Corporation's current dividend yield is 1.14% with a payout ratio of 39.6%.
What are Stryker Corporation's profit margins?
Stryker Corporation has 64.0% gross margin and 19.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Stryker Corporation have?
Stryker Corporation's Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.